Tactile Systems Technology, Inc. (TCMD) Fundamental Analysis: Bull vs. Bear Case

TCMD

Tactile Systems Technology, Inc.

Fundamental data last updated:October 8, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Medical - Devices

Exchange

NASDAQ

County of HQ

US

Next Earnings Date

Pending Announcement

Business Summary

Tactile Systems Technology, Inc., a medical technology company, engages in the development and provision of medical devices for chronic diseases in the United States. The company offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema; Entre system, a portable pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers; and AffloVest, a portable high frequency chest wall oscillation test for the treatment of retained pulmonary secretions such as bronchiectasis, cystic fibrosis, and various neuromuscular disorders. The company was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.

VALUATION

P/E

28.29 Market Cap ($M USD)

$574.06M

Forward P/E

11.41 PEG

0.08 PRICE TO SALES

1.67 PRICE TO BOOK

2.64 EV / EBITDA

12.59 5-Year Average P/E

Free Cash Flow Yield

6.83%

DCF Value

$63.59

Graham Number

$13.98

Price to FCF

14.64 EV to FCF

13.11 Earnings Yield

3.53%

FCF Yield

6.83%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$0.90

Next Year EPS Growth Estimate

$2.23

Next Year Revenue Growth Estimate

$436.61M

Return on Equity (ROE)

9.70%

FREE CASH FLOW

Operating Margin

9.40%

Debt-to-Equity

0.07 Piotroski F-Score

8 Altman Z-Score

8.72 Return on Invested Capital (ROIC)

13.67%

Current Ratio

4.24 Quick Ratio

3.78 Net Debt to EBITDA

-1.46

Interest Coverage

71.91 Gross Profit margin

75.68%

FCF PER SHARE

$1.74

REVENUE PER SHARE

$15.23

Gainseekers Quantitative Analysis

Summary

TCMD’s valuation presents a compelling opportunity for deep value investors. Recent pricing indicated it traded significantly below its DCF value, suggesting a market mispricing. The Forward P/E of 11.50 and an impressive Altman Z-score of 8.87 highlight both growth potential and financial stability. With an Earnings Yield of 3.51%, the stock offers a reasonable return relative to its price, reinforcing its attractiveness. The market seems to underestimate TCMD’s intrinsic value, making it a potential gem for discerning investors.

AI Exposure / Tech Reliance

Operating in the Medical Devices sector, TCMD is well-positioned to leverage AI and tech advancements. The healthcare industry is increasingly integrating AI for diagnostics and patient care, which could enhance TCMD's product offerings. This adaptability is crucial for maintaining competitive advantage in a rapidly evolving market.

The Bull Case

For value investors, TCMD shines with its robust ROIC of 13.67% and a Piotroski F-Score of 8, indicating strong financial health and operational efficiency. The company's Free Cash Flow Yield of 6.78% underscores its ability to generate cash, while a Gross Profit Margin of 75.68% reflects significant pricing power. These metrics suggest TCMD is capitalizing on its resources effectively, making it an attractive buy for those seeking growth at a reasonable price.

The Bear Case

Despite its strengths, TCMD faces challenges with its valuation multiples. The Price/Book ratio of 2.66 and Price/Sales of 1.68 may deter investors wary of paying a premium. Additionally, the stock's proximity to its 52-week high, with a distance of 47.25%, suggests potential overextension. While its debt levels are low, the market's current pricing could limit upside potential, posing a risk for new entrants.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$39.25

Institutional Ownership %

1-Year Beta

0.82 Insider Buying % (6 Mo)

Distance to 52-Week High

48.41%

Distance to 52-Week Low

63.01%

EARNINGS SURPRISE %

-14.29%

50-DAY SMA

$24.84

200-DAY SMA

$23.03

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.